Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

AMRX - Amneal Pharmaceuticals, Inc.... | Finranks

Home

/

AMRX

A

Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Цена в реальном времени. Валюта: USD

17.28

+0.18 (1.05%)

Рынок открыт: Aug 12, 2026, 11:22 AM EDT

17.05

-0.05 (-0.29%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Видео

No Data

There is no data to display

Пресс-релизы

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization.